Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: Gilead Sciences, Inc. is far larger — about 24.8× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| GILD | SPXL | |
|---|---|---|
Market Cap | $182.40B | $7.36B |
Volume | 4,469,821 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $301.38 |
52-Week Low | $117.18 | $170.20 |
Typical Hold Time | 111 Days | 32 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
SPXL, a leveraged ETF tracking the S&P 500, trades at $293.05, down 1.28% on the day. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETF reflects broader market sentiment where S&P 500 earnings are expected to grow 35% in 2026 (24/7 Wall Street, 2026-10-03), yet concerns about profit growth slowing to 15% in 2027 and high concentration in top holdings create uncertainty.
The outlook for SPXL is tied to S&P 500 performance, with Wall Street projecting a 21% rise to 9,275 by September 2027 (The Motley Fool, 2026-09-30). Key risks include market volatility, geopolitical tensions, and slowing earnings growth. Opportunities lie in seasonal bullish trends and AI-driven corporate spending, but leveraged exposure amplifies both gains and losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
